Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders

  title={Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders},
  author={Robert G. Priest and R. Gimbrett and Matthew Roberts and J. Steinert},
  journal={Acta Psychiatrica Scandinavica},
The clinically tested reversiblc inhibitors of monoamine oxidase A (RIMAs) include brofaromine, moclobemide and toloxatone. Moclobemide has shown unequivocal antidepressant activity against serious deprcssivc illness in 4 placebo‐controlled double‐blind trials. It has been compared with amitriptyline, imipramine, clomipramine, desipramine, maprotiline, fluoxetine, fluvoxamine, tranylcypromine. toloxatone, mianserin and amineptine in the treatment of depressive disorders. Meta‐analysis showed… 
Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma
A comprehensive survey of the natural products, predominantly from plant sources, as potential new MAOI drug leads, and characterization of MAO inhibitory constituents of natural products traditionally used as psychoactive preparations or for treatment of neurological disorders may help in understanding the mechanism of action.
Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression
4‐fluorotranylcypromine, a novel monoamine oxidase inhibitor: Neurochemical effects in rat brain after short‐ and long‐term administration
It is demonstrated that FTCP is a more potent inhibitor of MAO ex vivo than is the parent drug, and that metabolic drug–drug interactions may be less of a concern with FTCP than with TCP.
Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs
The behavioural effects of acute and chronic treatments with the reversible monoamine oxidase-A inhibitors (RIMAs) moclobemide and befloxatone in the Mouse Defence Test Battery suggest that befl oxatone may have some efficacy in the clinical management of panic.
Pharmacotherapy Of Selective Mutism: Two Case Studies Of Severe Entrenched Mutism Responsive To Adjunctive Treatment With Fluoxetine
It is proposed that a possible pharmacological rationale for the adjunctive use of 5HT selective agents in this disorder, which appears to be a childhood variant of social phobia, panic or separation anxiety disorder, is proposed.
Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats
  • E. Garland
  • Psychology
    Journal of psychopharmacology
  • 1998
Based on short- and intermediate-term studies to date, stimulant medication is clearly more efficacious than cognitive and behavioral strategies for the symptoms of ADHD, and indications for long-term stimulant treatment of ADHD present some controversy.
Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats.
The need for more options in pharmacotherapy of ADHD is evidenced by rapid adoption in clinical practice of alternative and adjunctive medication despite lack of controlled research on efficacy and safety.


Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders
In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia,
Reversible monoamine oxidase-A inhibitors in panic disorder.
A randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia achieved a significant and comparable reduction in the number of panic attacks.
A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
In the present double-blind study Moclobemide has been compared to placebo in a group of 34 unipolar psychotic or neurotic depressed patients and results have shown that the active drug was markedly superior to placebo.
Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants
  • R. Priest
  • Psychology, Biology
    Acta psychiatrica Scandinavica. Supplementum
  • 1990
In all 5 studies comparing moclobemide with imipramine there was no statistically significant difference in efficacy, and the lack of substantial difference suggests that the drugs may well be of similar potency.
Recent advances in antidepressant drugs.
Moclobemide is a RIMA that has proved itself to be very effective in severe depressive illness and may be expected to be associated with a high acceptability in depressed patients.
RIMA — A new concept in the treatment of depression with moclobemide
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent that is devoid of any clinically significant tyramine interaction, thus making dietary restrictions during therapy unnecessary.
Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
The therapeutic efficacy of brofaromine--a new reversible and short acting MAO-A inhibitor--was evaluated in 14 patients with a panic disorder and a distinct improvement in both anxiety and depressive symptoms was observed under the active drug.
A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine.
Neuronal Lipopigment: A Marker for Cognitive Impairment and Long-Term Effects of Psychotropic Drugs
  • J. Dowson
  • Biology
    British Journal of Psychiatry
  • 1989
Chronic administration of agents which can be correlated with decreased neuronal lipopigment in animal models might protect neuronal function against any adverse effects associated with (but not necessarily resulting from) lipopIGment accumulation in normal ageing, anoxia, or certain degenerative diseases.